Australia's most trusted
source of pharma news
Thursday, 09 May 2024
Posted 18 January 2022 PM
In a potential win for ovarian cancer patients, GSK's Zejula has gained TGA approval, opening the way to PBAC consideration in March.
The drug was listed on the reimbursement committee's agenda for its next meeting when it was released late last year among a slew of new products yet to be approved by the regulator.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.